RxSight Increases FY23 Revenue From $81M-$86M To $85M-$87M Vs $83.93M Est.
Portfolio Pulse from Benzinga Newsdesk
RxSight has increased its FY23 revenue guidance from $81M-$86M to $85M-$87M, representing a growth of 73% to 78% compared to 2022. The company also raised its gross margin guidance to 60%-61% from 58%-60% and narrowed its operating expense guidance to $106M-$107M, an increase of 25%-26% compared to 2022.
November 09, 2023 | 9:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RxSight's increased revenue and gross margin guidance for FY23 indicates strong growth prospects, which could positively impact its stock price in the short term.
The increased revenue and gross margin guidance indicates that RxSight is expecting strong performance in FY23. This positive outlook could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100